



November 14, 2024

To: British Columbia Securities Commission  
Ontario Securities Commission  
Canadian Securities Exchange

Fahn Kanne & Co.  
Head Office  
32 Hamasger Street  
Tel-Aviv 6721118, ISRAEL  
PO Box 36172, 6136101

T +972 3 7106666  
F +972 3 7106660  
www.gtlk.co.il

Dear Sirs / Mesdames

**Re: DiagnosTear Ltd. (“DiagnosTear”)**

We refer to the prospectus of Oceanview Technologies Inc. (the “Prospectus”) dated November 14, 2024 relating to the qualification of certain securities issuable by Oceanview in connection with the reverse takeover transaction with DiagnosTear.

We consent to being named, and to the use in the above-mentioned Prospectus, of our reports dated September 29, 2024 to the shareholders of DiagnosTear on the following financial statements:

1. Statements of financial position as at December 31, 2023 and 2022.
2. Statements of loss and comprehensive loss, statements of changes in the shareholders' equity and statements of cashflows for the three years ended December 31, 2023, and a summary of material accounting policies and other explanatory information.

We report that we have read the Prospectus and all information therein and have no reason to believe that there are any misrepresentations in the information contained herein that are derived from the financial statements upon which have been reported or that are within our knowledge as a result of our audit in such financial statements. We have complied with Canadian generally accepted standards for an auditor's consent to the use of a report of the auditor included in an offering document, which does not constitute an audit or review of the long form of prospectus as these terms are described in the CPA Canada Handbook - Assurance.

Yours sincerely,

FAHN KANNE & CO. GRANT THORNTON ISRAEL

Tel-Aviv, Israel